預(yù)防性生物制品15類(lèi)，凍干人用狂犬病疫苗臨床試驗(yàn)批件轉(zhuǎn)讓。有意向，能洽談，有合作。   [更多]

1、針對(duì)于疫苗類(lèi)生物制品；2、適合疫苗臨床前研究的研發(fā)企業(yè)；3、按照國(guó)家2018年7月發(fā)布的《藥品臨床試驗(yàn)用藥物質(zhì)量管理規(guī)范》建立的質(zhì)量體系文件；4、包括程序文件，標(biāo)準(zhǔn)操作規(guī)程，記錄等   [更多]

求購(gòu)雷米普利原料及片最新權(quán)威標(biāo)準(zhǔn) BP2019版藥典標(biāo)準(zhǔn)和USP42版藥典標(biāo)準(zhǔn)   [更多]

求購(gòu)：USP Monographs: Temozolomide for Injection”《 USP41-NF36 》的美國(guó)藥典（USP41-NF36 ）標(biāo)準(zhǔn)一份   [更多]

提供藥廠(chǎng)及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱(chēng)，聯(lián)系方式，信息需真實(shí)可靠。   [更多]

求購(gòu)“USP Monographs: Teriparatide Injection”《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份.   [更多]

“Formulated Preparations: Specific Monographs: Inositol Nicotinate Tablets”《 BP2019 》的藥典標(biāo)準(zhǔn)一份.   [更多]

最好能附帶原料藥標(biāo)準(zhǔn)   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]